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Carbon monoxide-releasing molecules (CO-RMs) are a class of organometallo compounds capable of delivering
controlled quantities of CO gas to cells and tissues thus exerting a broad spectrum of pharmacological effects.
CO-RMs containing transition metal carbonyls were initially implemented to mimic the function of heme
oxygenase-1 (HMOX1), a stress inducible defensive protein that degrades heme to CO and biliverdin leading to
anti-oxidant and anti-inflammatory actions. Ten years after their discovery, the research on the chemistry and
biological activities of CO-RMs has greatly intensified indicating that their potential use as CO delivering agents for
the treatment of several pathological conditions is feasible. Although CO-RMs are a class of compounds that
structurally diverge from traditional organic-like pharmaceuticals, their behaviour in the biological environments is
progressively being elucidated revealing interesting features of metal-carbonyl chemistry towards cellular targets.
Specifically, the presence of carbonyl groups bound to transition metals such as ruthenium, iron or manganese
appears to make CO-RMs unique in their ability to transfer CO intracellularly and amplify the mechanisms of signal
transduction mediated by CO. In addition to their well-established vasodilatory activities and protective effects
against organ ischemic damage, CO-RMs are emerging for their striking anti-inflammatory properties which may be
the result of the multiple activities of metal carbonyls in the control of redox signaling, oxidative stress and cellular
respiration. Here, we review evidence on the pharmacological effects of CO-RMs in models of acute and chronic
inflammation elaborating on some emerging concepts that may help to explain the chemical reactivity and
mechanism(s) of action of this distinctive class of compounds in biological systems.
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Bactericidal activitiesIntroduction
The heme oxygenase enzymes (HMOX1 and HMOX2)
generate, among other interesting molecules, the gas
carbon monoxide (CO) [1]. The quantity of the gas pro-
duced over time depends on the tissue examined, as
HO-2 is constitutively expressed in the endothelium, tes-
tes and brain while HMOX1 is highly inducible in all tis-
sues by many kinds of stressful stimuli [2]. In addition,
the availability of the substrate heme, which is cleaved
by heme oxygenases in the α position to release CO, will
strictly determine how much CO can be produced in the
cell. However, it is expected that CO levels will increase* Correspondence: roberto.motterlini@inserm.fr; roberta.foresti@inserm.fr
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reproduction in any medium, provided the orupon up-regulation of HMOX1 and this has been
demonstrated in some studies that directly measured
CO production ex-vivo [3,4]. Research conducted in the
past years has progressively elucidated the role of
HMOX1 in mammalian systems. The protein was recog-
nized early on as an important component of the stress
response [5,6] but it was only when detailed exploration
of the function of its products was performed that an in-
dispensable action for HMOX1 as an anti-oxidant and
anti-inflammatory system emerged [7,8]. CO appears to
contribute most significantly to these anti-inflammatory
activities by regulating a variety of transcription factors,
inflammatory proteins and pathways [9-11]. This role
is consistent across many inflammatory conditions,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Motterlini et al. Medical Gas Research 2012, 2:28 Page 2 of 12
http://www.medicalgasresearch.com/content/2/1/28although the specific pathways affected might differ from
one disease to another.
Exposure of cells, tissues and animals to sub-toxic
amounts of CO gas has been used successfully to repro-
duce the anti-inflammatory properties of HMOX1 and
has helped to unravel many of the mechanisms under-
lying this effect [10,11]. The use of CO gas as a thera-
peutic agent is also underscored by clinical trials
currently ongoing in patients who will receive CO by in-
halation for the treatment of pulmonary arterial hyper-
tension, post-operative ileus and idiopathic pulmonary
fibrosis (see www.clinicaltrials.gov). In parallel and as an
alternative to this experimental approach, we have fo-
cused our strategy on utilizing chemicals that could bind
and carry CO stably but deliver the gas when used in
biological systems. We have identified and termed these
compounds CO-releasing molecules (CO-RMs) [12-14]
and have extensively studied their biochemical, bio-
logical and pharmacological effects in many in vitro and
in vivo models of disease [9,15-17]. The chemical struc-
ture of the best characterized CO-RMs (CORM-2,
CORM-3, CORM-A1 and CORM-376) is represented in
Figure 1 (see also chemical formula in List of Abbrevia-
tions). Thanks to strong collaborations with chemists,
we have generated CO-RMs with improved water solu-
bility, diverse chemical structures, various rates of CO
release and stability [9,15,58-60]. The results have been
encouraging as the concentrations and doses of CO-
RMs used in all studies were such that the final CO
exposure was below the threshold believed to cause tox-
icity. In addition, as shown in Table 1, the data obtained
so far support promising pharmacological actions of
CO-RMs that could be useful to counteract inflamma-























Figure 1 Chemical structure of the best characterized CO-RMs which
activities in vitro and in vivo (see also Table 1 for more details).ruthenium, iron or manganese as metal center, and bora-
nocarbonates are the two major classes of CO-RMs in
our portfolio [15,16,59,61]. Our own investigations and
studies with collaborators revealed that metal carbonyls
are better anti-inflammatory agents than boranocarbo-
nates but the reasons for this difference are unknown at
present. The chemistry and pharmacological pro
perties of these compounds is becoming a topic of
great interest since in the last 2-3 years other research
groups have synthesized a variety of different new
CO-RMs. Recently ruthenium imidazole oxime car
bonyls [62], photoactive and nanoCO-RMs [63,64],
enzyme-triggered CO-RMs [65], CO-RMs encapsulated
in micelles [66] and rhenium-based CO-RMs [67] have
been developed. However, for most of these new mole-
cules a detailed picture of their behaviour in cells, tis-
sues and in vivo models of disease is not yet available,
and will be required to evaluate their full pharmaco-
logical potential. In this context it is important to
emphasize that, once CO is liberated, the potential tox-
icity of the residual molecule containing the transition
metal needs to be carefully evaluated. To date a sys-
tematic in vivo toxicological profile of CO-RMs has not
yet been performed but this will be required once a
lead compound will be identified for a given patho-
logical indication.
In this article we will review the role of CO-RMs in
protection against inflammatory conditions, focusing
primarily on their effect on oxidative stress and nitric
oxide (NO) production, two of the main initiators of the
inflammatory cascade. The biochemical and physio-
logical assays used to determine CO liberation or trans-
fer of CO to cellular targets and their interesting
























have been shown to exert anti-inflammatory and anti-bacterial
Table 1 Effect of CO-RMs on in vitro and in vivo inflammatory disease models
Type of CO-RM Inflammatory disease models Effect on inflammatory markers/ References
in vitro and in vivo Overall outcome
CORM-3 Vascular thrombosis in rats ↓ fibrinogen and fibrin [18]
↑ pro-thrombin
CORM-3 Hemorrhagic stroke induced by collagenase in rats ↓ TNF-α production [19]
↓ brain injury
CORM-2 Polymicrobial sepsis induced by cecal ligation and perforation (CLP) in
mice
↑ protein C system [20]
↓ plasma thrombomodulin
↓ number of thrombi in liver, kidney and
lung




↓ Serum levels of IL-6, alkaline
phosphatase and
MMP-3
CORM-2 Coagulation and fibrinolitic markers in human umbilical vein endothelial
cells (HUVEC)
↓ tissue factor [22]
↓ plasminogen activator inhibitor type 1
(PAI-1)
CORM-2 Neuropatic pain and microglia activation in mice induced by nerve injury ↓ mechanical allodynia [23]
CORM-3 ↓ thermal hyperalgesia
↓ nNOS and iNOS expression
↓ microglial marker (CD11b/c)
CORM-3 Vascular inflammation in human umbilical vein endothelial cells (HUVEC) ↓ VCAM-1 and ECAM expression [24-26]
CORM-2 ↓ NF-kβ and p38-MAPK expression
↓ mitochondrial respiration
↓ NF-kβ and iNOS expression
CORM-2 Ischemia-reperfusion injury after kidney transplantation in rats ↑ survival rate [27]
CORM-3 ↓ acute tubular necrosis and
hemorrhage
CORM-2 Colitis induced by dextran sodium sulfate in mice ↓ disease activity index [28]
↓ myeloperoxidase (MPO) activity
↓ TNF-α production
CORM-2 Endoplasmic reticulum (ER) stress induced by thapsigargin in human
hepatocytes and mice
↓ C-reactive protein (CRP) [29]
CORM-3 ↓ serum amyloid P component (SAP)




↓ TNF-α production and ICAM-1
expression
↑ IL-10 production
CORM-2 Acute hepatic ischemia-reperfusion injury in rats ↑ anti-apoptotic protein Bcl2 [31]
↓ markers of hepatic damage (AST/ALT)
↓ serum levels of TNF-α and IL-6
↓ caspase activity and NF-kβ expression
CORM-2 Acute pancreatitis in rats ↓ serum levels of TNF-α and IL-1β [32]
↓ NF-kβ expression and MPO activity
↑ IL-10 production
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Table 1 Effect of CO-RMs on in vitro and in vivo inflammatory disease models (Continued)
CORM-3 Rheumatoid arthritis induced by KBxN serum transfer in mice ↑ serum osteocalcin and HO-1
expression
[33]
↓ MMP-9, MMP-13 and IL-1β expression
↓ high mobility group box 1 (HMGB1)
↓ Receptor activator of nuclear factor κB
ligand (RANKL)
CORM-2 Ischemia-reperfusion induced inflammation of small intestine in mice ↓ TNF-α and ICAM expression [34]
↓ leukocytes rolling and adhesion
↓ NF-kβ expression and MPO activity
CORM-2 Inflammatory response induced by lipopolysaccharide in RAW 264.7
macrophages and BV-2 microglia
↓ iNOS mRNA and protein expression [35]
↑ COX-2 expression and NF-kβ
expression
↑ PGE2 levels
↑ phosphorylation of Akt and MAPKs
CORM-2 Sepsis induced by cecal ligation and puncture (CLP) in mice ↓ neutrophil infiltration in broncoalveolar
lavage and liver
[36-39]
↓ MPO activity in lung and NF-kβ in liver
↓ serum TNF-α and high mobility group
box 1 (HMGB1)
↓ nitrite/nitrate plasma levels
↑ cardiac PGC-1α and mitochondrial
biogenesis
CORM-A1 Inflammatory response induced by TNF- α in brain vascular endothelial
cells
↓ NADPH oxidase activity [40]
↓ apoptosis
CORM-3 Post-operative ileus in mice ↑ intestinal contractility and transit [41]
CORM-A1 ↑ IL-10 and HMOX1 expression
↓ IL-6 and iNOS expression
↓ leukocyte infiltration
CORM-2 Inflammatory response in liver and small intestine of thermally injured
mice
↓ TNF-α, IL-1β and iNOS expression [42,43]
↓ leukocyte infiltration
↓ NF-kβ and ICAM-1 expression
CORM-3 Bacterial activity in vitro and bacterial infection in vivo ↓ E. Coli and P. Aeuruginosa growth
in vitro
[17,44-48]
CORM-2 ↑ bacteriostatic and bactericidal effects
in vivo
CORM-A1 ↑ increased phagocytosis in vivo
CORM-371 ↓ respiration in bacteria
ALF-021 ↑ survival after bacterial infection in vivo
ALF-062 ↓ high mobility group box 1 (HMGB1)
CORM-3 Collagen-induced arthritis in mice ↓ prostaglandin E2 (PGE2) [49]
↓ pro-inflammatory interleukins (IL-1β,
IL-2, IL-6)
↑ anti-inflammatory interleukins (IL-10)
↓ expression of cyclooxygenase-2 (COX-
2)
CORM-3 Vascular inflammation in human neutrophils and rat primary endothelial
(EC) and mast (MC) cells
↓ oxidative burst in human PMNs [50]
↓ expression of CD54 in rat ECs
↓ histamine in MCs
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Table 1 Effect of CO-RMs on in vitro and in vivo inflammatory disease models (Continued)
CORM-2 Inflammatory response induced by pro-inflammatory cytokines in Caco-2
cells and human chondrocytes
↓ prostaglandin E2 (PGE2) and nitrite [51-53]
↓ ROS production
↓ COX-2 and iNOS protein expression
↓ NF-kβ expression
↓ metalloproteinase-7 (MMP-7)
CORM-3 Leukocyte-endothelial interaction in vitro and in a models of acute
pancreatitis and paw edema in mice
↓ PMNs leukocytes in peritoneal cavity [54]
CORM-A1 ↓ PMNs rolling on endothelial cells
↓ paw edema and swelling
CORM-3 Inflammatory response induced by LPS/INFγ and hypoxia in BV2 microglia
cells
↓ nitrite and TNF-α production [55,56]
↓ hypoxia-reoxygenation damage
CORM-2 Inflammatory response induced by lipopolysaccharide in RAW 264.7
macrophages
↓ nitrite and TNF-α production [57]
CORM-3
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Inflammation and host defense are necessary and intrin-
sic processes that serve to protect organisms from a
series of pathological challenges. The mechanisms that
accompany the inflammatory response involve multiple
cell types, signalling pathways and transcriptional factors
and inflammation appears to be relevant for the vast
majority of chronic diseases as well as in acute condi-
tions [68]. That HMOX1 is a key player in mitigating
inflammation was first reported in a model of
carrageenin-induced pleurisy in rats, in which the evolu-
tion of inflammation was accompanied by a dramatic in-
crease in HMOX1 levels and inhibition of heme








Figure 2 Graphical representation summarizing the mechanism(s) po
(see text for details).In addition, HMOX1 deficiency in human subjects
exhibited high levels of vascular inflammation and oxi-
dative stress [70], a finding which is highly reproducible
in mice lacking this stress protein [71]. Although biliru-
bin and biliverdin, endowed with potent antioxidant
properties, may be important contributors that fight in-
flammation [72,73], CO gas applied exogenously is often
found to recapitulate many of the anti-inflammatory
actions elicited by HMOX1 [74]. Our work on the dis-
covery and characterization of CO-RMs was carried out
while novel findings by Otterbein et al. described the
powerful effect of CO gas in inhibiting the production of
pro-inflammatory cytokines (TNF-α, IL-1β) stimulated














tentially involved in the anti-inflammatory activities of CO-RMs
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the anti-inflammatory cytokine IL-10 and that mitogen
activated protein kinases (MAPKs) mediated this
phenomenon [8]. This and other exciting work stimu-
lated our efforts in the development of CO-RMs and in
trying to understand their efficacy in disease models.
From an anti-inflammatory perspective, CO-RMs can
affect multiple cell types and pathways that coordinate
the inflammatory cascade (see Table 1 for a summary of
the anti-inflammatory activities of CO-RMs in various
in vitro and in vivo models). For example, Urquhart et al
found that CORM-3 strongly reduced neutrophil ex-
travasation in the peritoneum of zymosan-treated mice
and inhibited expression of adhesion molecules in
human polymorphonuclear neutrophils (PMNs) [54].
Still focusing on PMNs, Sun and co-workers showed
that CORM-2 attenuated the leukocyte sequestration,
Nfkβ activation and endothelial protein expression of
ICAM-1 in the lung of thermally injured mice [75]. The
multiple effects of CO-RMs were particularly well dis-
sected in a study by Masini et al. where human PMNs
primed to elicit an inflammatory response were co-
incubated with rat endothelial cells or perivascular mast
cells [50]. Here the authors clearly showed that CORM-3
down-regulated the oxidative burst in PMNs, the
over-expression of adhesion molecules in PMNs and
endothelial cells and the release of histamine and up-
regulation of an activation marker by mast cells. These
results indicate how CORM-3 modulates acute inflamma-
tion by reducing the activation of PMNs, the first respon-
ders in host defense, but also by inhibiting expression of
molecules and inflammatory factors that perpetuate the
inflammatory process. In RAW macrophages and BV-2
microglia we have also shown concentration-dependent
decreases in nitrite and TNF-α production by CORM-2
and CORM-3 following challenge with LPS [55-57].
The in vivo anti-inflammatory action of CO-RMs has
also been consistently described. The group of Alcaraz
has performed a series of detailed investigations in arth-
ritis models [21,33,49] and demonstrated that daily treat-
ment with CORM-2 or CORM-3 can effectively
suppress the clinical and histopathological manifesta-
tions of disease. Levels of PGE-2 and many other inflam-
matory mediators were reduced in the joint and this
resulted in a better preservation of cartilage tissue and
bone structures [33]. However, modulation of inflamma-
tory molecules levels surely is not the only mechanism
contributing to the CO-RMs mediated protection
against inflammation and the data by Lancel and collea-
gues point to mitochondria as very important cellular
organelles that are affected by CO-RMs. In a model of
sepsis induced by cecal ligation, CORM-3 administration
conserved cardiac mitochondrial function by preventing
sepsis-mediated damage to mitochondria thus preservingmembrane potential and respiration and inducing mito-
chondrial biogenesis [36]. In the heart of mice fed a high fat
diet to mimic a metabolic syndrome-like disorder CORM-3
also stimulated mitochondrial biogenesis [76]. The mode of
action and efficacy of CO-RMs may also depend on the
timing of administration in relation to the pathology stud-
ied, as exemplified recently by our investigation in a model
of hemorrhagic stroke in rats [19]. Indeed, we observed that
CORM-3 pre-treatment (5 min) or post-treatment (3 days)
of rats after the onset of the hemorrhage elicited protective
effects while administering the compound 3 hours after the
stroke, in correspondence to the acute phase of the disease
process, resulted in exacerbation of damage. The striking
observation of this study is that one single dose of CORM-3
could modify the long-term inflammatory scenario
that followed the hemorrhagic stroke by redirecting
and limiting the infiltration of peripheral leukocytes
and neutrophils in the brain and reducing the local
activation of brain microglia and astrocytes induced
by the stroke. Importantly, CORM-3 appeared to
finely tune the levels of TNF-α, by allowing its positive ac-
tion in reparatory processes but inhibiting its detrimental
effects. Thus, a growing body of literature supports a bene-
ficial role of CO-RMs in inflammatory models but future
investigations are required to better establish their thera-
peutic applications (see Figures 2 and 3 for the proposed
mechanism of action of CO-RMs in vitro and in vivo).Mechanisms underlying the effects of CO-RMs on
inflammation: modulation by oxidative stress
It is well accepted that inflammatory stimuli promote a
variety of responses that participate to exacerbate dam-
age in cells and tissues but also promote the resolution
of inflammation. Oxidative stress, derived from excessive
and persistent production of reactive oxygen species
(ROS) and a possible decrease in antioxidant defences,
accompanies or precedes the increased amounts of
inflammatory mediators upon inflammatory challenge.
Because CO has a high affinity for different heme-
containing proteins – cytochromes in mitochondria and
NADPH oxidase in the cell [77] - that contribute to
regulate the levels of ROS, it is intriguing that part of
the anti-inflammatory activities of CO-RMs may derive
directly from inhibiting the generation of these dam-
aging (or signalling) species. CO-RMs have shown a ten-
dency to modulate pathways that produce ROS and the
chemical nature of transition metal carbonyls might
favour this reaction by allowing a selective transfer of
CO from the CO-RMs to the target [78,79]. In RAW
macrophages treated with LPS or PMA-stimulated neu-
trophils CORM-2 inhibited NADPH activity and over-
production of superoxide anion (O2
−) [80]. Similarly,
CORM-A1 reduced the accumulation of ROS induced
CO 
Regulation of mitochondrial  
respiration and biogenesis 
Bactericidal activity 
CO-RM 
Inhibition of platelet  
aggregation and thrombosis 
Inhibition of leukocyte  
adhesion and rolling 
Attenuation of oxidative and  
nitrosative stress 
Figure 3 Schematic diagram representing the diverse effects of CO liberated from CO-RMs in vitro and in vivo (see text for details).
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possibly by acting on a specific subunit of NADPH oxi-
dase (Nox4) which is highly expressed in these cells
[40,81]. Notably, a reduction in oxidative stress was
reported also in chondrocytes from cartilage specimens
of patients suffering from osteoarthritis, emphasizing
both the relevance of these findings in primary human
tissue and the idea that pathological processes occurring
in diseased tissue can be modified by application of
CO-RMs [51]. Oxidative stress levels were also signifi-
cantly reduced by CORM-3 in intestinal tissue in a clin-
ically relevant model of postoperative ileus and this was
accompanied by partial restoration of antioxidant cap-
acity levels [41]. Increased production of ROS following
TNF-α/cycloheximide exposure was also diminished by
CORM-A1 in a mouse intestinal epithelial cell line [82].
In summary, different CO-RMs can inhibit ROS/oxida-
tive stress that results from inflammation, thus affecting
an early and crucial mechanism that modulates subse-
quent inflammatory processes (see Figure 2).
Mechanisms underlying the effects of CO-RMs on
inflammation: modulation of inducible nitric oxide
synthase (iNOS) and NO production
Inflammation is a complex phenomenon; thus, it is
anticipated that any anti-inflammatory properties of
CO-RMs would involve a number of metabolic pathway.
Overproduction of NO following up-regulation of indu-
cible NO synthase (iNOS) is a critical step in the initi-
ation and propagation of the inflammatory response [83]
and diverse actions of CO-RMs in relation to this system
have been described although with quite conflicting
findings. We have observed that CORM-2 and CORM-3
decrease NO levels produced by macrophages stimulated
with LPS without affecting iNOS protein expression [57]
and because of these results we have postulated that CO
from CO-RMs inhibited the activity of iNOS, a heme-
containing protein already shown in purified form to beblocked by CO gas [84]. Similar results were obtained in
microglia by Min KJ et al. [85] while Megias and collea-
gues actually demonstrated that iNOS expression was
reduced by CORM-2 in Caco-2 cells challenged with a
combination of IL-1β, TNF-α and IFN-γ [52]. Other
authors have reported the same observation in the gut
[41] and in the spinal cord [23] following inflammatory
damaging conditions, strengthening the idea that indeed
CO-RMs exert an inhibitory effect on iNOS induction
and activity. This would not perhaps be surprising if we
consider that CO-RMs seem to affect the activation of
Nfkβ [24,25,52], which controls the expression iNOS
and is a master regulator of major pathways in inflam-
mation. However, until detailed studies designed to dis-
sect the effect of CO-RMs on activity versus induction
of iNOS are performed, it will not be clear whether
CO-RMs can inhibit NO generation or iNOS expression.
It may well be that inhibition of both can occur simul-
taneously or that one effect or the other will prevail de-
pending on the inflammatory condition, tissue analyzed
and the type of CO-RM investigated.
Bactericidal activities of CO-RMs
The threat of bacterial infection is omnipresent in surgi-
cal settings, wounds and contaminated food, any of
which may lead to fatal consequences. Interestingly,
CO-RMs have been shown to possess anti-bacterial
properties that may be among the important therapeutic
applications envisioned for this class of compounds.
Lack of HMOX1 in mice resulted in an exaggerated le-
thality after cecal ligation and puncture (CLP), which
caused polymicrobial sepsis [86]. However, the adminis-
tration of CORM-2 was able to increase phagocytosis,
decrease circulating bacterial counts, and rescue
HMOX1–/– mice from the exaggerated mortality of
CLP-induced sepsis, even when applied 6 hours after the
initiation of infection. This is a remarkable result that
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actions in such a complicated and severe pathological
scenario. Desmard et al. also demonstrated that CORM-3,
CORM-2 and, to a lesser extent, CORM-371, exert anti-
bacterial actions against P. Aeruginosa in vitro and in vivo
[17,87]. The ruthenium-based CO-RMs appeared more ef-
fective and CORM-A1 only exerted a transient bacterio-
static action, highlighting again the importance of the metal
in mediating some activities of CO-RMs and perhaps guid-
ing CO to the appropriate cellular target. More detailed
work has been performed to investigate the direct effect of
CO-RMs on different bacteria and the results have been
reviewed elsewhere [88,89].
Using more biochemical-oriented approaches, it has
been possible to determine that terminal oxidases are
targeted by CORM-3 when inhibiting bacterial growth
[17,44], thus impairing bacterial respiration. Moreover,
oxidative stress caused by CO-RMs is another factor
explaining some mechanistic actions of these com-
pounds. According to Tavares et al., exposure of E. Coli
to CORM-2 or a molybdenum-containing CO-RM
increased the levels of intracellular ROS as well as caus-
ing DNA damage and disruption of Fe-S clusters [45].
The authors also showed that thiol-based antioxidants
prevented the anti-microbial properties of CO-RMs, a
finding we corroborated in studies using P. Aeruginosa
[17,87]. However, in our work no effect of CORM-2 or
CORM-3 on ROS production was detected as assessed
by the use of a fluorescent probe [17], while in another
collaborative investigation it was observed that thiols
reduced the ROS production stimulated by CORM-2 in
P. Aeruginosa biofilms but that this reduction was not
accompanied by inhibition of bacterial growth [46].
Thus, the collective evidence suggests that CO-RMs
interacts with metal-based proteins present in bacteria
to exert various effects that are related to their bacteri-
cidal or bacteriostatic properties. However, it is possible
that other pathways, susceptible to changes following ap-
plication of CO-RMs, contribute to CO-RMs-mediated
anti-microbial effects. In this regard, data obtained from
microarray analysis of bacterial genes affected by expos-
ing E. Coli to CORM-2 and CORM-3 have provided fas-
cinating information about the pathways responding to
CO-RMs [44,90]. It should be noted that one study
looked at aerobically and anaerobically grown E Coli and
CORM-2 while the other investigated CORM-3 in an-
aerobically grown E Coli, thus already indicating that dif-
ferent results should be expected from this analysis.
Saraiva and colleagues have nicely summarized the di-
verse, and perhaps still incomplete, information col-
lected in these two transcriptomic approaches showing
that some pathways are typically changed in anaerobic
conditions, some only in the aerobic state and some are
instead commonly altered in E Coli grown either inaerobic or anaerobic conditions [88]. Of interest, genes
involved in zinc homeostasis and the bacterial response
to oxidative stress (SoxRS and OxyR) were increased in
both conditions, perhaps stressing that, irrespective of
the growth medium, the presence of ruthenium in
CO-RMs and their propensity to cause oxidative stress/
inhibit the respiratory complexes will consistently occur.
The fact that genes modulating biofilm pathways are
affected is also a clear signal that E. Coli is suffering
from exposure to CO-RMs and thus attempts to boost
its resistance to these agents by promoting biofilm for-
mation. In addition, increased methionine metabolism is
triggered by CO-RMs, which may still be linked to an
oxidative stress response.
In summary, few, but well designed and informative
reports support the idea that CO-RMs are useful com-
pounds to be employed alone or in combination with
other antibiotics [46] to fight bacterial infection, taking
into account the important notion that the bactericidal
actions of CO-RM-s are elicited at concentrations that
do not harm mammalian cells [17].
Liberation of CO by CO-RMs: biochemical and
pharmacological assays
Assessing CO liberation from CO-RMs has been a prior-
ity since our discovery of these compounds. Initially we
developed a myoglobin assay for the detection of carbon
monoxy myoglobin (MbCO) and employed an ampero-
metric CO electrode to determine the rate and quantity
of CO released [12,16]. Gas chromatography techiques
have also been used by others to assess the spontaneous
liberation of CO from CO-RMs in solution. In parallel,
we used bioassays such as relaxation of aortic vessels
and inhibition of the inflammatory response in macro-
phages to assess the CO-mediated pharmacological
effects of CO-RMs [12,57,91]. In most cases we found a
very good correlation between the rate and mode of CO
release by CO-RMs and their effect on aortic ring relax-
ation. The results from several studies have also enabled
us to propose that the chemical structure of metal car-
bonyls CO-RMs might facilitate the direct transfer of
CO from CO-RMs to the intracellular target(s) as it
appears that the release of CO from certain metal carbo-
nyls (i.e. CORM-2 and CORM-3) requires an acceptor
[17,44,92]. This may enhance selectivity for the action of
CO from metal carbonyls and the difference with CO
gas applied exogenously would be that its diffusion into
cells might be limited or hampered by the encounter of
many proteins potentially able to bind CO, including the
prototypic intracellular target(s) [17,77]. Although this
concept needs to be substantiated, results on the bacteri-
cidal effects of CO-RMs (see above) and an interesting
article published recently reports data in this direction.
Wang and colleagues have developed a genetically
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ively detecting CO inside living cell [93]. The probe,
named COSer for CO sensor, consists of a permuted yel-
low fluorescent protein inserted into the regulatory do-
main of the bacterial protein CooA, a heme-dependent
transcription factor known to bind CO with high affinity
and selectivity. It was found that the fluorescent inten-
sity of HeLa cells transfected with COSer increased after
addition of 5 μM CO gas and a higher response was
obtained with 10 μM. Interestingly, the fluorescence in-
tensity was even stronger in cells treated with CORM-2
as a very significant response was obtained with only 1
μM CORM-2 and to obtain a given fluorescence inten-
sity, more CO gas was needed with COSer-transfected
cells than with the purified probe. These findings led the
authors to state that CORM-2 provided an alternative
and more controllable method for CO delivery to cells
and could have possibly reduced the difficulty they
encountered in getting CO into cells by using simple
CO solutions. Similar findings were recently obtained by
Michel and co-workers, who have synthesized a
palladium-based fluorescent probe that is capable of
detecting CO with high selectivity both in aqueous solu-
tions and in living cells. Notably, CORM-3 was used in
their experiments as the source of CO revealing that,
unlike CO gas, concentrations as low as 1 μM CORM-3
were sufficient to trigger fluorescence in cells loaded
with the palladium probe [94].
The use of the MbCO assay to assess the rate and
amount of CO liberated by CO-RMs has been recently
questioned [95]. In our experiments we showed that
while MbCO is promptly formed after addition of
CORM-2 or CORM-3 to a solution containing reduced
Mb, a sensitive CO electrode failed to detect any CO
upon addition of these two CO-RMs [17]. However, CO
release from CORM-A1, a boranocarbonate, is detected
by the Mb assay and by the electrode with comparable
results, indicating the spontaneous liberation of CO
from the compound. McLean and colleagues have shown
that in the case of CORM-3 and CORM-2 liberation of
CO and the consequent formation of MbCO is facili-
tated by dithionite, which is usually added in excess to
the assay for keeping Mb in a reduced state [95]. The
authors concluded that the MbCO assay should be aban-
doned and propose the use of hemoglobin (Hb) since it
binds CO with a much greater affinity than oxygen and
does not require deoxygenation by dithionite. We be-
lieve these data indicate that dithionite and other
sulphite can accelerate the release of CO from CO-RMs
and that rates of CO release obtained with the MbCO
assay should be interpreted cautiously, but we would like
to add few important considerations still in favour of the
MbCO assay. First, the results by McLean and collea-
gues seem to imply that liberation (or transfer) of COfrom CORM-2 and CORM-3 to a prototypic target
(i.e. Mb) cannot occur in the presence of a deoxygenated
reduced heme but is triggered only by interaction with
anions such as sulphites. That this is not the case is ele-
gantly described by Obirai and colleagues in an interest-
ing report published few years ago revealing quite the
opposite as CORM-2 was demonstrated to directly
transfer CO to a heme(FeII)/heme(FeIII) redox couple
[92]. Using a cyclic voltammetry method, the authors
proved that when CORM-2 is added to an argon deaer-
ated phosphate buffer solution containing an electrode
coated with the heme redox couple but in complete ab-
sence of dithionite, a heme(FeII)-CO complex is formed.
Secondly, the determination of the rate of CO liberation
from CO-RMs by using an in vitro biochemical assay is
rather approximate and we always judged it best to in-
terpret our data on CO liberation using a combination
of approaches as these compounds are designed for their
possible therapeutic use in vivo. That is the reason why
in our studies on the characterization of CO-RMs we al-
ways coupled the quantification of CO liberation in vitro
with data obtained using bioassays that reflect more
closely the behaviour of these compounds in complex
biological systems. For instance, despite the fact that
CORM-2 and CORM-3 are stable compounds in solu-
tion and may not liberate CO spontaneously, they still
cause a rapid relaxation in isolated vessels and
hypotension in animals suggesting that these compounds
are fast CO releasers in vivo in line with the MbCO
assay data. The bioactive effects mediated by the rapid
CO release from these two CO-RMs have been corrobo-
rated by using pharmacological tools (i.e. inactive
CO-RMs or CO-RMs depleted of CO) [15,57,91] or by
comparison with compounds that release CO much
slower in vitro and in vivo (i.e. CORM-A1 and CORM-371)
[16,17]. As a further example, we have recently employed
the MbCO assay to determine that CORM-401, a
manganese-containing CO-RM, liberates 3-4 CO per
molecule [60]. We found that the relaxation exerted by this
molecule in aortic rings is approximately 3-fold more
pronounced than that elicited by the same concen-
tration of CORM-A1, which has a half-life similar to
CORM-401 but liberates only 1 CO (unpublished
results). Third, the use of oxygenated Hb instead of
reduced Mb poses other relevant issues, such as the
presence of 4 hemes and the co-operative effect of
CO binding to the hemes, which will make it more
difficult to quantify the amount and kinetics of CO
released. These considerations, together with the
results of the MbCO assay and the recent findings with the
fluorescent probes reported above, strongly indicate that
the release of CO from CORM-2 and CORM-3 occurs
when the metal carbonyl is in the vicinity of a reduced iron
acceptor (MbFe(II) or heme(II)). The results have also
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CO-RMs in delivering CO to prototypic intracellular
targets.
Conclusions
Although the initial discovery of CO-RMs took place a
decade ago [12], it is intriguing that many diverse and
novel pharmacological actions are being discovered for
these compounds. The studies conducted so far reflect a
real effort to understand the biochemical mechanisms
that mediate the beneficial effects of CO-RMs. The
emerging scenario is that, while CO-RMs mainly affect
cellular functions via the liberation of CO, the molecules
may facilitate or modulate other concomitant reactions
involving redox and metal-sensitive pathways. Import-
antly, the chemical reactivity of metal carbonyl
complexes-based CO-RMs may be enriching, rather than
diminishing, their positive actions suggesting that a crit-
ical assessment of CO-RMs’ behaviour in biological en-
vironment (bioassays) must always be evaluated in
parallel to their ability to release CO. In view of the
growing importance of inflammatory components in ini-
tiating and modulating pathological processes, we have
focused here on how CO-RMs modulate the inflamma-
tory response as consistent and converging data point to
their interesting anti-inflammatory activity. As new CO-
RMs with a multiplicity of chemical properties and re-
activity are being synthesized and tested in biological
models, we may in the future uncover novel promising
applications for this unique class of compounds.
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